381 related articles for article (PubMed ID: 20452958)
1. Single-nucleotide polymorphisms in the p53 signaling pathway.
Grochola LF; Zeron-Medina J; Mériaux S; Bond GL
Cold Spring Harb Perspect Biol; 2010 May; 2(5):a001032. PubMed ID: 20452958
[TBL] [Abstract][Full Text] [Related]
2. Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population.
Wu GC; Zhang ZT
Med Oncol; 2015 Jan; 32(1):401. PubMed ID: 25479941
[TBL] [Abstract][Full Text] [Related]
3. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.
Sun T; Lee GS; Oh WK; Pomerantz M; Yang M; Xie W; Freedman ML; Kantoff PW
Clin Cancer Res; 2010 Nov; 16(21):5244-51. PubMed ID: 20855462
[TBL] [Abstract][Full Text] [Related]
4. MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia.
Ebid GT; Sedhom IA; El-Gammal MM; Moneer MM
Asian Pac J Cancer Prev; 2012; 13(9):4315-20. PubMed ID: 23167335
[TBL] [Abstract][Full Text] [Related]
5. Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma.
Qiu M; Liu Y; Yu X; Qin L; Bei C; Zeng X; Qiu X; Tang B; He S; Yu H
Tumour Biol; 2016 Mar; 37(3):3863-70. PubMed ID: 26476535
[TBL] [Abstract][Full Text] [Related]
6. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
7. p53 Signaling Pathway Polymorphisms Associated With Emphysematous Changes in Patients With COPD.
Mizuno S; Ishizaki T; Kadowaki M; Akai M; Shiozaki K; Iguchi M; Oikawa T; Nakagawa K; Osanai K; Toga H; Gomez-Arroyo J; Kraskauskas D; Cool CD; Bogaard HJ; Voelkel NF
Chest; 2017 Jul; 152(1):58-69. PubMed ID: 28315337
[TBL] [Abstract][Full Text] [Related]
8. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans.
Bond GL; Levine AJ
Oncogene; 2007 Feb; 26(9):1317-23. PubMed ID: 17322917
[TBL] [Abstract][Full Text] [Related]
9. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G
Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750
[TBL] [Abstract][Full Text] [Related]
10. Common genetic variants in the TP53 pathway and their impact on cancer.
Barnoud T; Parris JLD; Murphy ME
J Mol Cell Biol; 2019 Jul; 11(7):578-585. PubMed ID: 31152665
[TBL] [Abstract][Full Text] [Related]
11. MDM2-p53 pathway in hepatocellular carcinoma.
Meng X; Franklin DA; Dong J; Zhang Y
Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
[TBL] [Abstract][Full Text] [Related]
12. Association between single nucleotide polymorphisms in the p53 pathway and response to radiotherapy in patients with nasopharyngeal carcinoma.
Xie X; Jin H; Hu J; Zeng Y; Zhou J; Ouyang S; Yang W; Hu B; Wang H
Oncol Rep; 2014 Jan; 31(1):223-31. PubMed ID: 24173110
[TBL] [Abstract][Full Text] [Related]
13. p53 Arg72Pro and MDM2 309 SNPs in hereditary retinoblastoma.
Epistolato MC; Disciglio V; Livide G; Berchialla P; Mencarelli MA; Marozza A; Amenduni M; Hadjistilianou T; De Francesco S; Acquaviva A; Toti P; Cetta F; Ariani F; De Marchi M; Renieri A; Giachino D
J Hum Genet; 2011 Sep; 56(9):685-6. PubMed ID: 21814224
[TBL] [Abstract][Full Text] [Related]
14. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
Lahiri O; Harris S; Packham G; Howell M
Cancer Genet Cytogenet; 2007 Nov; 179(1):36-44. PubMed ID: 17981213
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
16. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.
Yang Y; Xia T; Li N; Zhang J; Yang Y; Cong W; Deng Q; Lan K; Zhou W
Protein Cell; 2013 Jan; 4(1):71-81. PubMed ID: 23292895
[TBL] [Abstract][Full Text] [Related]
18. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer.
Han JY; Lee GK; Jang DH; Lee SY; Lee JS
Cancer; 2008 Aug; 113(4):799-807. PubMed ID: 18618574
[TBL] [Abstract][Full Text] [Related]
19. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
20. The p53 G72C and MDM2 T309G single nucleotide polymorphisms in patients with Wegener's granulomatosis.
Assmann G; Wieczorek S; Wibisono D; Roemer K; Arning L; Voswinkel J
Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S72-5. PubMed ID: 18799058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
